How 2025 ACA marketplace formularies are adjusting tier placement for gene-silencing drugs like Amvuttra after CMS’s new specialty cost threshold update

How 2025 ACA Marketplace Formularies Are Adjusting Tier Placement for Gene-Silencing Drugs Like Amvuttra After CMS’s New Specialty Cost Threshold Update

The 2025 plan year brought a clear shift: the Centers for Medicare & Medicaid Services (CMS) raised the specialty drug cost threshold for Affordable Care Act (ACA) marketplace plans. That update is already changing how high-cost gene-silencing drugs, including Amvuttra (vutrisiran), are positioned in formularies. Pharmacists and benefits teams are noticing new cost-sharing patterns as exchange plans adapt their tiering for some of the most expensive therapies now included in Qualified Health Plans (QHPs).

Background: The Gene-Silencing Therapy Class

Gene-silencing therapies rely on RNA interference (RNAi) or antisense oligonucleotide mechanisms to dampen production of harmful proteins. They’re mostly developed for ultra-rare genetic disorders and are priced accordingly, often hundreds of thousands of dollars a year. Once they move from trials into real-world use, insurers must decide how to balance equity, actuarial fairness, and federal benefit-design standards. That’s the hard part.

Amvuttra, made by Alnylam Pharmaceuticals, earned FDA approval in 2022 for hereditary transthyretin-mediated amyloidosis (hATTR). It’s a subcutaneous small-interfering RNA (siRNA) drug that limits transthyretin (TTR) formation in the liver. SSR Health puts its U.S. list price around $463,500 per year. No surprise, it sits squarely in the specialty tier for virtually every exchange plan.

The 2025 CMS Specialty Drug Threshold

CMS raised the specialty-tier threshold for ACA plans to $670 per 30‑day supply, up from $550. That move tracks with the overall jump in drug acquisition costs. If a medication exceeds that figure, it’s eligible for the specialty tier, as long as cost-sharing and placement follow nondiscrimination and benefit-design limits.

Plans can now use more than one specialty tier when cost or utilization justify the distinction. That flexibility matters for drugs like Amvuttra, grouped beside gene therapies, CAR‑T treatments, and antisense oligonucleotides. CMS basically acknowledged that “specialty” now spans a huge price range, and that payers need more than one bucket to handle it.

How Formulary Teams Are Responding

Each spring, issuers submit their QHP formulary structures to regulators. Public 2025 filings show the new normal: two specialty layers. Drugs costing under roughly $10,000 per month fall into “Specialty Tier 1,” while those over that mark go into a higher specialty tier. Amvuttra, Givlaari (givosiran), and Onpattro (patisiran) mostly land in the top category with coinsurance between 30% and 50%. And yes, that’s steep, but those tiers hit the out-of-pocket cap relatively quickly.

Some Blue Cross Blue Shield affiliates, Illinois, North Carolina, Florida, already display identical tiering for these RNAi drugs. In tighter regulatory states such as Massachusetts and California, plans can only use one specialty tier but offset it with higher coinsurance. Either way, cost exposure starts heavy at the pharmacy counter before the cap kicks in.

Typical Tier Placement Across Select 2025 QHP Formularies

These placements come from CMS 2025 formulary filings. They show payers separating RNAi agents by price bands, not mechanism or outcome, even when patient groups overlap.

Where the Rule Meets Actuarial Reality

Under the ACA, cost-sharing has to fit within each plan’s Actuarial Value (AV) tier, Bronze, Silver, Gold, or Platinum. High-cost drugs weigh heavily in those calculations. CMS clarified for 2025 that even therapies covered under prior authorization or patient-assistance programs still count in AV math. Issuers have to walk a fine line between affordability and Essential Health Benefits (EHB) compliance.

The new threshold lets insurers move moderately expensive biologics down toward preferred brand tiers, freeing space for ultra‑priced therapies like Amvuttra on the top rung. That keeps the math consistent. Still, patient groups worry this quietly pushes more initial spending onto individuals before the out‑of‑pocket cap resets everything.

Defining “Specialty” in 2025

Per CMS, specialty-tier status applies to any drug exceeding the $670 benchmark for a 30‑day supply. Plans can’t exceed EHB cost limits or single out disease groups. What’s new is disclosure: if a plan has multiple specialty tiers, it has to show each tier name and maximum cost for the standardized fill quantity. Transparency is the real change here.

This ties directly to the revamped HealthCare.gov Plan Finder. During the 2025 Open Enrollment, the tool displayed drug-tier names and coinsurance rates right next to premiums. CMS testing showed roughly two‑thirds of users checked at least one drug before picking a plan. That feedback loop is already shaping how issuers label specialty drugs.

Actuarial Implications and Rate Filings

Analyses from Milliman and Wakely show specialty drugs consuming nearly 60% of QHP drug spend in 2025 while making up less than 2% of total prescriptions. The higher threshold reduced short-term plan liability slightly by shifting some early-month costs to enrollees. But it didn’t meaningfully move overall premium trends, those are driven mostly by medical inflation elsewhere.

Still, rate filings tell a story. Several carriers explicitly called out gene‑silencing therapies in actuarial memos, citing annual costs above $400,000 as major contributors to specialty trend assumptions of roughly 20% over two years. Actuaries no longer treat these as one‑off anomalies. They’re baking them into long‑term forecasts.

Patient Access and Non‑Discrimination Rules

Even at the highest tier, a drug like Amvuttra must remain covered under EHB and nondiscrimination standards. Insurers can use prior authorization, step therapy, or quantity limits, but not deterrence through exclusion. In federally managed exchanges, those utilization policies have to be filed and published each year.

For 2025, CMS requires urgent prior authorization decisions within 72 hours and non‑urgent within seven days. That timeline also applies to specialty drugs. Patients gain predictability, although costs stay substantial. Fair trade, at least in theory.

Copay Accumulators and Maximizers

Manufacturer assistance is again colliding with plan design. Some 2025 exchange plans exclude drugmaker copay help from counting toward out‑of‑pocket maximums, while others smooth it across the year through “maximizer” setups. HHS kept the federal rule unchanged for 2025, leaving decisions to states. As of early 2026, 19 states plus D.C. require at least partial inclusion of manufacturer support in cost‑sharing tallies. That difference matters, especially when a $40,000 annual copay card determines whether a patient hits their cap by February or never.

PBM Contract Shifts for Marketplace Issuers

Pharmacy Benefit Managers had to catch up. Most adopted the $670 threshold internally to keep rebate and formulary definitions aligned. Several added an “ultra‑specialty” classification, basically a quarantine zone for six‑figure drugs like Amvuttra and its peers.

In states pooling PBM administration (think Texas or Minnesota), this structure helps normalize contract terms. Shared tier definitions simplify rebate benchmarks and service fees. Plan filings in those exchanges specifically cited the change when renewing 2025 PBM contracts.

Manufacturer Strategy and Rebate Dynamics

Manufacturers in this space rarely offer deep rebates, they can’t, given the complexity and tiny patient pools. Evaluate Pharma data show median rebates under 10% for RNAi products. CMS now asks issuers to disclose gross‑to‑net assumptions when certifying formularies, effectively forcing justification for prominent tier placement when rebates are minimal.

Instead, drugmakers expand patient‑support channels. Alnylam runs “Alnylam Assist,” offering copay aid and navigation for exchange enrollees who qualify. Those programs live under tight legal scrutiny, anti‑kickback rules still apply, but they’re a practical lifeline while plan designs catch up.

The Economic Weight of the Threshold Bump

CMS and KFF modeling suggest a Silver‑plan member with a $9,450 out‑of‑pocket max could owe over $2,500 the first month of Amvuttra before coverage takes over. After that, the plan absorbs the rest. That initial spike deters some patients from starting therapy early in the year. Advocacy groups have lobbied for “payment smoothing,” but there’s no federal requirement yet.

Insurers counter that caps prevent worst‑case scenarios. Once the limit is hit, costs fall to zero for the remainder of the year. So premiums stay stable, even with eye‑watering monthly invoices. The threshold and cap together form an uneasy equilibrium, keeping both plan budgets and patient exposure somewhat predictable.

What’s Next Going Into 2026

CMS intends to keep the threshold formula and simply index it to inflation. That would push it past $700 for a 30‑day supply next year if current pricing trends persist. A handful of forthcoming RNAi and mRNA therapies could test this setup again. The question is less about price now and more about classification: where do these new drugs land on the specialty map?

Insurers look ready to expand transparency requirements rather than compress tiers. The ones that clearly lay out tier logic and member costs tend to face smoother state review, and fewer consumer surprises. Look, clarity wins even when affordability doesn’t.

Takeaway for Patients and Benefits Teams

The 2025 CMS specialty‑cost adjustment sounds technical but ripples through every part of plan design and patient affordability. Gene‑silencing therapies like Amvuttra deliver extraordinary outcomes but come at market‑shifting cost levels. For benefits managers, understanding how these tiers work helps forecast member expense. Pharmacists see why coverage applies steep coinsurance even when a drug is technically “covered.” And patients, if they know their out‑of‑pocket max and the limits of copay assistance, they’re better prepared for the shock upfront.

As these marketplace formularies evolve, what keeps them functional is coordination among CMS, states, PBMs, and manufacturers. That, and a bit of honesty about who pays when the next half‑million‑dollar therapy arrives.

Medical and insurance disclaimer: This article is for informational purposes only and does not provide medical advice, legal guidance, or benefit selection recommendations. Consult a licensed health insurance professional, pharmacist, or healthcare provider for advice tailored to your specific circumstances.